The recent reports of Tamiflu resistance has prompted the World Health Organization to recommend "boosted antiviral treatment for hospital patients with severely weakened immune systems who contract swine flu." WHO maintained that there had been "no evidence" that the reported cases represented a wider public health threat, but "reiterated calls for vigilance and modified treatment advice for the frontline flu drug."
Cervarix may protect against HPV for more than six years.
Cervarix, one of two FDA-approved vaccines against human papillomavirus (HPV), protects against infection for more than six years, researchers found." In a Lancet paper, researchers reported that through "follow-up as long as 6.4 years, the vaccine had an efficacy of 95.3% for preventing infection with the two types of HPV most commonly implicated in cervical cancer -- HPV-16 and -18." In addition, Cervarix was found to be "100% effective at preventing cases of cervical intraepithelial neoplasia grade 1 and above, the investigators reported."
“Wellness" blog also notes that previous "research has shown that the equivalent vaccine, Gardasil, from fellow pharmaceutical giant Merck, protects for up to five years."
Novavax H1N1 vaccine study seen as meeting goals.
Novavax Inc. announced that its H1N1 flu vaccine proved safe and effective in a study conducted in Mexico." Novavax "said that the vaccine, which uses lab-created virus-like particles rather than the entire live virus strain, produced favorable initial results from the first stage of a two-stage pivotal Phase II study." Based on the findings, the company also "said it has been cleared to proceed to a second stage of testing in which vaccine safety will be evaluated in 3,000 subjects with a single dose regimen." An independent panel said the vaccine was well tolerated at three dose levels and showed no systemic side effects.
Lenalidomide plus bortezomib may be promising for relapsed, refractory multiple myeloma.
Lenalidomide (Revlimid) combined with bortezomib (Velcade) appears to be a promising treatment for patients with relapsed and refractory multiple myeloma," according to a study published in the Journal of Clinical Oncology. Researchers found that "overall, the combination treatment was well tolerated." But, in an accompanying editorial, Jesús F. San Miguel, MD, of the University of Salamanca in Spain, noted that "similar results have been observed with combination therapy that includes bortezomib, cyclophosphamide, and dexamethasone, or lenalidomide, doxorubicin, and dexamethasone," which "could be considered as an...argument in favor of the sequential rather than simultaneous use of bortezomib and lenalidomide."